Neurim Pharmaceuticals Gains EU Approval for Pediatric Melatonin to Treat Insomnia in Children with ADHD
March 26, 2025 | 07:00
Neurim Pharmaceuticals ("Neurim") announces that the European Commission has approved the extension of the indication to include the treatment of insomnia in children with attention deficit hyperactivity disorder (ADHD).
Mobile Version